Back to Search
Start Over
Pharmacokinetics and pharmacodynamics of piperacillin-tazobactam in 42 patients treated with concomitant CRRT.
- Source :
-
Clinical journal of the American Society of Nephrology : CJASN [Clin J Am Soc Nephrol] 2012 Mar; Vol. 7 (3), pp. 452-7. Date of Electronic Publication: 2012 Jan 26. - Publication Year :
- 2012
-
Abstract
- Background and Objectives: Current recommendations for piperacillin-tazobactam dosing in patients receiving continuous renal replacement therapy originate from studies with relatively few patients and lower continuous renal replacement therapy doses than commonly used today. This study measured the pharmacokinetic and pharmacodynamic characteristics of piperacillin-tazobactam in patients treated with continuous renal replacement therapy using contemporary equipment and prescriptions.<br />Design, Setting, Participants, & Measurements: A multicenter prospective observational study in the intensive care units of two academic medical centers was performed, enrolling patients with AKI or ESRD receiving piperacillin-tazobactam while being treated with continuous renal replacement therapy. Pregnant women, children, and patients with end stage liver disease were excluded from enrollment. Plasma and continuous renal replacement therapy effluent samples were analyzed for piperacillin and tazobactam levels using HPLC. Pharmacokinetic and pharmacodynamic parameters were calculated using standard equations. Multivariate analyses were used to examine the association of patient and continuous renal replacement therapy characteristics with piperacillin pharmacokinetic parameters.<br />Results: Forty-two of fifty-five subjects enrolled had complete sampling. Volume of distribution (median=0.38 L/kg, intraquartile range=0.20 L/kg) and elimination rate constants (median=0.104 h(-1), intraquartile range=0.052 h(-1)) were highly variable, and clinical parameters could explain only a small fraction of the large variability in pharmacokinetic parameters. Probability of target attainment for piperacillin was 83% for total drug but only 77% when the unbound fraction was considered.<br />Conclusions: There is significant patient to patient variability in pharmacokinetic/pharmacodynamic parameters in patients receiving continuous renal replacement therapy. Many patients did not achieve pharmacodynamic targets, suggesting that therapeutic drug monitoring might optimize therapy.
- Subjects :
- Academic Medical Centers
Acute Kidney Injury blood
Acute Kidney Injury metabolism
Adult
Aged
Alabama
Anti-Bacterial Agents administration & dosage
Anti-Bacterial Agents blood
Chromatography, High Pressure Liquid
Drug Monitoring
Female
Humans
Kidney Failure, Chronic blood
Kidney Failure, Chronic metabolism
Linear Models
Male
Middle Aged
Multivariate Analysis
Ohio
Penicillanic Acid administration & dosage
Penicillanic Acid analogs & derivatives
Penicillanic Acid blood
Penicillanic Acid pharmacokinetics
Piperacillin administration & dosage
Piperacillin blood
Piperacillin pharmacokinetics
Piperacillin, Tazobactam Drug Combination
Prospective Studies
Acute Kidney Injury therapy
Anti-Bacterial Agents pharmacokinetics
Kidney Failure, Chronic therapy
Renal Dialysis
Subjects
Details
- Language :
- English
- ISSN :
- 1555-905X
- Volume :
- 7
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- Clinical journal of the American Society of Nephrology : CJASN
- Publication Type :
- Academic Journal
- Accession number :
- 22282479
- Full Text :
- https://doi.org/10.2215/CJN.10741011